In this article included in The Globalisation of the Pharmaceutical Industry, the authors draw on their experience to develop lessons on how to establish a sustainable life sciences eco-system in middle-income countries (MICs) and low-income countries (LICs). They highlight the importance of different types of government policy (industrial policy, the regulatory framework, intellectual property, and improving access to medicines) and how success requires different stakeholders (public and private, international and national) to work together.
To read the article, click here.
Most Favored Nation pricing in the US
At the 2026 JP Morgan Healthcare Conference, CRA hosted an expert panel session with health policy experts from the US, Germany, and the UK to discuss the...

